Hwail Pharmaceutical Co., Ltd.

As of March 31, 2026, Hwail Pharmaceutical Co., Ltd. carries a market capitalization of 82.49B, placing it among publicly traded companies globally. Its enterprise value stands at -1.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Hwail Pharmaceutical Co., Ltd. has 8.42M shares outstanding.

As of March 31, 2026, Hwail Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 81.46. The price-to-sales ratio is 0.87, and the price-to-book ratio stands at 0.40.

As of March 31, 2026, Hwail Pharmaceutical Co., Ltd. maintains a current ratio of 23.32, meaning it holds 23.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.17, indicating conservative leverage, while an interest coverage ratio of -7.80 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Hwail Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 0.49, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.64, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.47, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.53, useful for judging operating efficiency across full business cycles. The company generates approximately 606.26M in revenue per employee across its workforce of 155.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.32 indicates how many times Hwail Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Hwail Pharmaceutical Co., Ltd. recorded 247.09M in income tax expense. That works out to an effective tax rate of 19.76, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.25B, leaving 1.00B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Hwail Pharmaceutical Co., Ltd.'s stock has declined approximately 47.66% over the past 52 weeks. The 50-day moving average sits at 7,433.60, while the 200-day moving average is 9,101.10.

Over the twelve months ended March 31, 2026, Hwail Pharmaceutical Co., Ltd. generated 94.27B in revenue and converted that into 1.00B in net income, yielding earnings per share of 120.30. EBITDA reached -884.06M, while operating income came in at -1.57B.

As of March 31, 2026, Hwail Pharmaceutical Co., Ltd. holds 84.59B in cash and equivalents against 353.23M in total debt, resulting in a net debt position of -65.85B. Total book value stands at 208.58B, with working capital of 134.20B providing operational flexibility.

Hwail Pharmaceutical Co., Ltd. produced 6.91B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -4.13B in capital expenditures, free cash flow totaled 2.78B - equivalent to 333.71 per share.

Over the twelve months ended March 31, 2026, Hwail Pharmaceutical Co., Ltd. posted a gross margin of 7.36, reflecting its pricing power and cost economics. The operating margin of -1.66 and net profit margin of 1.06 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 3.41, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hwail Pharmaceutical Co., Ltd. shareholders.

Hwail Pharmaceutical Co., Ltd.'s most recent stock split took place on May 4, 2026 with a 10:1 split ratio.

As of March 31, 2026, Hwail Pharmaceutical Co., Ltd. has an Altman Z-Score of 9.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.